Abstract
Pulmonary arterial hypertension is a serious disease with significant morbidity and mortality. Although it can occur idiopathically, it is more commonly associated with other cardiac or lung diseases. While most of the available therapies have been tested in adult populations and most therapies in children remain off-label, new reports and randomized trials are emerging that inform the treatment of pediatric populations. This review discusses currently available therapies for pediatric pulmonary hypertension, their biological rationales, and evidence for their clinical effectiveness.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1130-1146 |
| Number of pages | 17 |
| Journal | Pediatric Clinics of North America |
| Volume | 59 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- Endothelin
- Nitric oxide
- Phosphodiesterase
- Prostacyclin
- Pulmonary hypertension
- Pulmonary vasculature
- Vasodilator
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Pharmacotherapy for Pulmonary Hypertension. / Steinhorn, Robin H.
In: Pediatric Clinics of North America, Vol. 59, No. 5, 10.2012, p. 1130-1146.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacotherapy for Pulmonary Hypertension
AU - Steinhorn, Robin H
PY - 2012/10
Y1 - 2012/10
N2 - Pulmonary arterial hypertension is a serious disease with significant morbidity and mortality. Although it can occur idiopathically, it is more commonly associated with other cardiac or lung diseases. While most of the available therapies have been tested in adult populations and most therapies in children remain off-label, new reports and randomized trials are emerging that inform the treatment of pediatric populations. This review discusses currently available therapies for pediatric pulmonary hypertension, their biological rationales, and evidence for their clinical effectiveness.
AB - Pulmonary arterial hypertension is a serious disease with significant morbidity and mortality. Although it can occur idiopathically, it is more commonly associated with other cardiac or lung diseases. While most of the available therapies have been tested in adult populations and most therapies in children remain off-label, new reports and randomized trials are emerging that inform the treatment of pediatric populations. This review discusses currently available therapies for pediatric pulmonary hypertension, their biological rationales, and evidence for their clinical effectiveness.
KW - Endothelin
KW - Nitric oxide
KW - Phosphodiesterase
KW - Prostacyclin
KW - Pulmonary hypertension
KW - Pulmonary vasculature
KW - Vasodilator
UR - http://www.scopus.com/inward/record.url?scp=84867070620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867070620&partnerID=8YFLogxK
U2 - 10.1016/j.pcl.2012.07.011
DO - 10.1016/j.pcl.2012.07.011
M3 - Article
VL - 59
SP - 1130
EP - 1146
JO - Pediatric Clinics of North America
JF - Pediatric Clinics of North America
SN - 0031-3955
IS - 5
ER -